Issue link: http://osercommunicationsgroup.uberflip.com/i/562622
C h a i n D r u g s t o r e D a i l y S u n d a y, A u g u s t 2 3 , 2 0 1 5 4 DAVID BIERNBAUM AND HIS TEAMS HAVE DRIVEN OVER 200 SUCCESSFUL OTC/HBC BRANDS David Biernbaum is President and Senior Consultant at David Biernbaum & Associates LLC, and is one of the con- sumer goods and retail industry's fore- most business development consultants and national sales specialists in the field of health and beauty, OTC and personal care. Biernbaum and his teams have had major impact on more than 200 brands since 1977, and as a consultant and also a nationwide "master broker," he continues to have the magical touch. The latest and greatest examples: Australian Dream Arthritis Cream, Australian Dream Back Pain Cream and TriCalm Hydrogel. Biernbaum said, "Australian Dream is a four-ounce jar of pain relief that retails for an average of $30 in drug stores like Walgreens, CVS and many of the regional drug chains and supermar- kets. At one of the drug chains, we're selling nearly 4,000 pieces per week at $30 per unit even when not on promo- tion!" Australian Dream is also sold as a two-ounce at Walmart, Target and a number of supermarkets, too. The brand has responded extremely well over these past two years to TV and radio advertis- ing. Biernbaum said, "We advertise every day of the year and we never stop." Biernbaum cautions that he doesn't take on all new clients. "After 35 years in this business, I am very particular and have strict criteria for the clients and brands I take on. I take on only products that offer the retailer points of differenti- ation, innovation, high productivity on HIGH-QUALITY GENERICS FROM SUN PHARMA Sun Pharmaceutical Industries, LLC (Sun Pharma) offers a range of high- quality generics across dosage forms, with strong portfolios in controlled substances and anticancers. Since its acquisition of URL Pharma it has been able to strengthen its product basket. The acquisition of DUSA with its patented business (Levulan ® and BLU- U ® blue-light device) allows the com- pany to initiate a presence in the der- matology device market. Sun Pharma believes the $70 bil- lion U.S. generic market offers a tremendous opportunity to bring to the patient high-quality pharmaceuticals made to exacting standards in FDA- approved plants both in the U.S. and in India. Starting with simple dosage forms, tablets and capsules, its range has now grown to encompass differentiated products such as nanoparticle-based injections for targeted drug delivery, lyophilized injections, auto-injections and controlled release products. Sun Pharma is one of the few generics companies that have manufac- turing both in the U.S. and India. Starting with one Indian and one U.S. mainland F D A - a p p r o v e d plant each in 1997, it now has six dosage form plants in the U.S., in addi- tion to three plants in India that are USFDA approved. Its Cranbury, New Jersey plant is designed to make con- trolled substance formulations. For API, it has three approved plants in India, in addition to a plant each in the U.S. (Chattem Chemicals) and Hungary. Continued on Page 85 Continued on Page 85 AN INDEPENDENT PUBLICATION NOT AFFILIATED WITH NACDS Lee M. Oser CEO and Editor-in-Chief Kim Forrester Jules Denton Paul Harris Associate Publishers Lorrie Baumann Editorial Director Jeanie Catron JoEllen Lowry Associate Editors Yasmine Brown Andre Gressieux Graphic Designers Caitlyn Roach Sarah Glenn Customer Service Managers Heather Canale Stacy Davis Savannah Green Tara Neal Show Logistics & Distribution Randal Fisher James Gennette Neil Hicks Sarah Robinson Account Managers Enrico Cecchi European Sales Chain Drugstore Daily is published by Oser Communications Group ©2015 All rights reserved. Executive and editorial offices at: 1877 N. Kolb Road, Tucson, AZ 85715 520.721.1300/Fax: 520.721.6300 www.osercommunicationsgroup.com European offices located at Lungarno Benvenuto Cellini, 11, 50125 Florence, Italy